Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

Abstract

The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there were no significant differences between the azacitidine and decitabine groups regarding ORR (44% vs. 52%), OS (26 vs. 22 center dot 9months), EFS (7 center dot 7 vs. 7 center dot 0months), and rate of leukaemic transformation (16% vs. 22% at 1year). In patients 65years of age, survival was significantly better in the azacitidine group (P=0 center dot 017). Patients who received decitabine experienced more frequent episodes of grade 3 or 4 cytopenia and infectious episodes. We found that azacitidine and decitabine showed comparable efficacy. Among patients 65years of age, survival was significantly better in the azacitidine group (ClinicalTrials.gov Identifier: NCT01409070).